Dr. Agarwal's Health Care Limited has received a regulatory report from Dr. Athiya Agarwal under SEBI SAST Regulation 10(6) confirming the completion of an inter-se share transfer. The transaction, completed on February 24, 2026, involved the acquisition of 14,85,822 shares representing 0.47% of the company's share capital through a gift transfer from Dr. Anosh Agarwal.

Transaction Completion Details

The completed share transfer represents an inter-se transfer between promoter group members who are immediate relatives. Dr. Athiya Agarwal filed the regulatory report on February 26, 2026, with both BSE Limited and National Stock Exchange of India Limited, confirming the completion of the previously disclosed transaction.

Regulatory Compliance Framework

The transaction was executed under the exemption provided in Regulation 10(1)(a)(i) of SEBI SAST Regulations, 2011, which covers inter-se transfers of shares amongst immediate relatives. Dr. Athiya Agarwal had previously filed the required prior intimation under Regulation 10(5) on February 6, 2026, within the specified timeline.

Updated Shareholding Pattern

The inter-se transfer has resulted in changes to individual shareholdings within the promoter group while maintaining the overall promoter group shareholding percentage. The regulatory filing confirms that there has been no change in the total shareholding of the promoter and promoter group after the inter-se transfer.

Stock Exchange Notification

The regulatory report was filed with both BSE Limited (Company Code: 544350) and National Stock Exchange of India Limited (Company Symbol: AGARWALEYE). The filing confirms that all disclosure requirements under SEBI SAST Regulations have been fulfilled, including the prior intimation and post-transaction reporting obligations.

The completed transaction represents a straightforward reorganization of shareholding within the promoter group, with no impact on the company's operational structure or public shareholding pattern. The gift transfer eliminates the requirement for making an open offer to public shareholders under the immediate relatives exemption provision.

Dr. Agarwal's Health Care Limited has announced that ICRA Limited has reaffirmed and assigned credit ratings for the company's debt facilities totaling ₹200 crores. The rating action was communicated through a letter dated February 23, 2026, and disclosed to stock exchanges in compliance with Regulation 30 of SEBI listing regulations.

Credit Rating Details

ICRA Limited has taken comprehensive rating actions across the company's debt portfolio, covering both existing facilities and enhanced limits.

Rating Significance

The ICRA AA- (Stable) rating indicates high credit quality with very low credit risk, while the ICRA A1+ rating for short-term facilities represents the highest safety regarding timely payment of financial obligations. The stable outlook suggests that the rating is unlikely to change in the near term.

Enhanced Credit Facilities

A significant development in this rating action is the enhancement of unallocated limits to ₹126.20 crores, for which ICRA has both reaffirmed existing ratings and assigned new ratings. These unallocated limits provide the company with flexibility to utilize funds across long-term and short-term requirements as per business needs.

Regulatory Compliance

The company has fulfilled its disclosure obligations under Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The communication was signed by Thanikainathan Arumugam, Company Secretary and Compliance Officer, ensuring proper corporate governance protocols.